HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

Benzinga Real-time News ·  Aug 20, 2022 04:10

Biotech psychedelics companyHAVN Life Sciences Inc. (OTC:HAVLF)recently closed the initial tranche of its financing pact with innovative fundAlpha Blue Ocean ("ABO"), previously announced on July 21, 2022.

Since its creation in 2017, ABO hasexecuted more than $1.5 billion in financial commitmentsand more than 90 ‎transactions, mostly within the life sciences sector, all around the globe.

Following the current first-tranche closing, HAVN issued to theinvestment fund managed by ABO "Global Corporate Finance Opportunities 17"a total $1,100,000 principal amount of senior unsecured convertible debenture as well as 189,393 common share purchase warrants for net proceeds of approximately $420,000.

Theconvertible debenture may...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment